 |
Click here to retrieve your archive of CME certificates obtained via HDCN
|

TBA |
Nephrology Quiz and Questionnaire: Fluid and Electrolyte and Glomerular Disease Cases.
Michael Emmett, MD, and Jai Radhakrishnan, MD |

TBA |
Controversies in Diagnosis and Treatment of Atherosclerotic Renovascular Disease
Stephen C. Textor, MD and Lance D. Dworkin, MD, FASN
|

TBA |
New Insights, Treatments, and Management Strategies for ADPKD
Arlene B. Chapman, MD and James P. Calvet, PhD
|

1.5 |
Novel Therapeutics for Fluid and Electrolyte Disorders
Joseph G. Verbalis, MD and Biff F. Palmer, MD
|

1.5 |
Treatment of Frequently Relapsing/Steroid Dependent Minimal Change Disease
(Hogg);
Evaluation and Treatment Approach to Steroid-Resistant Primary FSGS in
Adults (Meyrier).
Ronald J. Hogg, MD and Alain Y. Meyrier, MD
|

1.5 |
Acute Kidney Injury.
Congestive Heart Failure: A Nephrologist's Disease? (Murray)
and AKI Therapeutics: From Bench to Commercialisation (Molitoris)
Patrick T. Murray, MD, FASN and Bruce A. Molitoris, MD
|

1.5 |
Renal Disease and the Metabolic Syndrome
Paul Muntner, PhD, and Linda F. Fried, MD, MPH
|

1.5 |
Physicochemical Factors in the Pathogenesis of Urinary Calculi (Worcester); Nephrolithiasis: A Bacterial Disease? Evidence Supporting and Against a Role of Nanobacteria in Calcium Stone Formation (Lieske)
Elaine M. Worcester, MD, FASN and John C. Lieske, MD, FASN
|

1.5 |
The Genetics of FSGS
Friedhelm Hildebrandt, MD, and Frederick J. Kaskel, MD, PhD, FASN
|

1.5 |
Primary Care Issues in Nephrology: Peripheral Vascular Disease:
Assessments and Approaches to Care (Froehlich);
Rheumatology for Nephrologists (Kay).
James B. Froehlich, MD, MPH, and Jonathan Kay, MD
|

1.5 |
Mycophenolate in Lupus and Non-Glomerular Renal Diseases
Leslie M. Shaw, PhD and Gerald B. Appel, MD, FASN
|

1.5 |
Aldosterone: New Insights in Kidney Health and Disease
David A. Calhoun MD and Mark E. Rosenberg, MD
|

1.5 |
Pre-ESRD and Mineral Metabolism
Kevin J. Martin, MB, BCh and Sharon M. Moe, MD
|

1.5 |
New Insights into Common Problems After Kidney Transplantation
Bertram L. Kasiske, MD and Jose R. Weisinger, MD
|

1.5 |
Challenges and Opportunities in the Treatment of Hyperuricemia and Gout
Richard Johnson, MD (moderator); Robert Terkeltaub, MD; Michael W. Rich, MD; Daniel Feig, MD, PhD, MS
|

1.5 |
New Treatments for Diabetes Mellitus: Implications for Clinicians
Robert Nelson, MD and George Bakris, MD
|

2.0 |
Medical Crossfire: Managing Phosphorus in CKD -- The Challenge Remains
David Bushinsky, MD (moderator); Geoffrey Block, MD, CCRI; Francisco Llach, MD; Rajnish Mehrotra, MD, FACP, FASN.
|

1.5 |
The Aging Kidney
Danilo Fliser, MD; George R. Aronoff, MD.
|

1.5 |
Phosphate Binders in CKD: An Update on Treatment Outcomes and Future Directions
Gérard M. London, MD (moderator); Craig B. Langman, MD; Markus Ketteler, MD.
|

1.5 |
Challenges in Volume Management. Optimizing Care in Patients with Heart Failure and Renal Dysfunction
John C. Burnett, MD; Michael B. Fowler, MBBS, FRCP, FACC; Mihai Gheorghiade, MD.
|

1.5 |
Contrast Media and CKD: What You Should Know About Contrast-Induced Nephropathy and Nephrogenic Systemic Fibrosis
Norbert Lameire, MD (moderator); Pontus B. Persson, MD, PhD; Michael V. Knopp, MD, PhD; Mark A. Perazella, MD
|

1.5 |
New Developments in Anemia Management in Chronic Kidney Disease
Dr. Adeera Levin, MD (moderator): Cindy Roy, PhD; Anatole Besarab, MD; Richard Amerling, MD, Arnold Berns, MD (discussant).
|

1.5 |
Navigating the Erythropoietin Stimulating Agent Landscape in CKD-Related Anemia
Jeffrey S. Berns, MD, FASN; Robert Provenzano, MD; Lynda Szczech, MD.
(Moderator: Jeffrey S. Berns, MD)
|
 |
To disseminate new knowledge regarding basic, translational, and clinical research discoveries in the field of nephrology.
|
 |
To provide exciting scientific and clinical advances in related disciplines in order to expand the scope of research and clinical care in nephrology.
|
 |
To discuss contemporary standards and new approaches to clinical care in order to ensure the highest quality of care for patients with renal diseases and related disorders.
|
 |
To review, update and put into perspective the recent advances in many key areas of general nephrology, dialysis, transplantation, and hypertension.
|
|
See Individual Lecture Pages
|
|  |
Each talk, or group of talks, depending
on length, is accredited
for the appropriate number of AMA PRA Category
1 Credits™.
Sometimes talks are organized
into groups of two or more
and paired with a single CME
post-test, which must be completed
along with an evaluation form.
|
| Date of Web Release: See
individual talks
Credit Eligible Through: April 30, 2009
Credits/Completion Time: See individual
talks
Target Audiences: Physicians, researchers, trainees.
Method of participation: Listen to the
talk, read the PubMed abstracts linked to data slides and talk references, take
the post-test, read the abstracts linked to post-test answer feedback material.
|
Chronic kidney disease affects 30-40 million Americans, of whom several
thousand require renal replacement therapy. These selected lectures
are chosen by the HDCN editor and ASN Postgraduate Medical Director
to reflect those areas of practice of greatest interest to the
clinician, and areas where recent progress has occurred. The
web extension of these ASN lectures will allow nephrologists
and other physicians who were unable to attend the live sessions
to gain similar benefit from these presentations.
ACCREDITATION AND DESIGNATION STATEMENTS: |
Accreditation Statement
The American Society of Nephrology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Credit Designation Statement: The American Society of Nephrology designates this educational activity AMA PRA Category 1 Credits™. Physicians should only claim credit commensurat with the extent of their participation in the activity.
All lectures selected were from Renal Week 2007, and all were put
together under supervision of the ASN Scientific
Program Committee. Web posting of lectures in the free zone was supported
by grants to the ASN from pharmaceutical companies. See each symposium
page for details of industry sponsorship and support.
FACULTY DISCLOSURE STATEMENTS : |
In accordance with the disclosure policies of the Accreditation Council for Continuing Medical Education (ACCME) and FDA guidelines, it is a policy at the ASN for individuals who are in a position to control the content of an educational activity to disclose to the activity participants: 1) the existence of all relevant financial relationships with any commercial interests or other relationships with the manufacturers of any commercial products/devices, or providers of commercial services, that relate to the content of their presentation/materials, or the commercial contributors of this activity, that could be perceived as a real or apparent conflict of interest; for this purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
Based on the disclosures provided, the ASN is responsible for identifying and resolving all conflicts of interest prior to presenting the educational activity to the learner. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that ASN CME activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty members were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.
Faculty disclosures are posted on each individual talk page.
DISCLOSURE OF UNLABELED USE: |
This educational activity may contain discussion of
published and/or
investigational uses of agents that are not indicated by FDA. The
American Society
of Nephrology and HDCN do not
recommend the
use of any agent outside of the labeled indications. Please refer
to the official
prescribing information for each product for discussion of approved
indications,
contraindications and warnings. Faculty disclosure about individual talks is posted on each individual talk page.
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not
meant to serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians
without evaluation of their patient's conditions and possible
contraindications on dangers in use, review of any applicable
manufacturer's product information, and comparison with recommendations
of other authorities.
To complete this educational activity, the user will need Windows (XP or higher) or Macintosh (version 9.0 or higher) operating
software, a connection to the internet with a 28.8 kbps MODEM or better. The computer should have
an audio card with speakers. An audio player, either the Windows Media Player (downloadable from www.microsoft.com)
the Real Player from Real Media (www.real.com) is required and either can be downloaded for free
per instructions on the individual lecture pages. Flash 8.0 (from www.adobe.com) is required to see the full-screen slide/audio presentations and the video presentations. Acrobat Reader is required to print the CME
certificate, and this can be download free from www.adobe.com.
For any questions concerning this specific activity please send
an email to
or email@asn-online.org,
or call HDCN at 630-325-3276, Monday through Friday from 10 AM - 4 PM Central Standard Time.
For any general questions concerning ASN CME, please contact the American Society of Nephrology.
| |